

Appropriate Treatment for Upper Respiratory Infection (URI)

By working together, we can improve health outcomes for your patients, our members. The Healthcare Effectiveness Data and Information Set (HEDIS[®]) helps us measure many aspects of performance. This tip sheet provides key details of the HEDIS measure for appropriate treatment for upper respiratory infection.

What is the measure?

The measure focuses on the number of episodes for members who are three months old and older who had a diagnosis of upper respiratory infection during the measurement year that **did not result** in an antibiotic prescription.

How to Improve Your Quality Score

This measure considers all eligible episodes so a patient can count more than once toward performance for a measurement year.

- Review and document the diagnosis and discuss the importance of not prescribing an antibiotic with your patient.
- Schedule follow-up appointments as needed.

Note: Compliance is met if the patient did not receive antibiotic medication during the episode period which is a four-day period spanning from the diagnosis event date to three days after the episode.

Compliance is determined independently for each eligible episode occurring in a measurement year.

Antibiotic Medications

Medication Type

Prescription(s)

Aminoglycosides

Amikacin, Gentamicin, Streptomycin, Tobramycin

Aminopenicillins

Amoxicillin, Ampicillin

Beta-lactamase inhibitors

Amoxicillin-clavulanate, Ampicillin sulbactam, Piperacillin-tazobactam

First generation cephalosporins

Cefadroxil, Cefazolin, Cephalexin

Fourth generation cephalosporins

Cefepime

Continued next page

All summaries of the measures contained herein are reproduced with permission from HEDIS *Volume 2: Technical Specifications for Health Plans* by the National Committee for Quality Assurance (NCQA). HEDIS[®] is a registered trademark of the NCQA. Please see the final page of this document for the full copyright citation.

Florida Blue is an Independent Licensee of the Blue Cross and Blue Shield Association.

103814 0323R

HEDIS Measure: Appropriate Treatment for Upper Respiratory Treatment (URI) *(continued)*

Antibiotic Medications

<u>Medication Type</u>	<u>Prescription(s)</u>
Lincomycin derivatives	Clindamycin, Lincomycin
Macrolides	Azithromycin, Clarithromycin, Erythromycin
Miscellaneous antibiotics	Aztreonam, Chloramphenicol, Dalfopristin-quinupristin, Daptomycin, Linezolid, Metronidazole, Vancomycin
Natural penicillin(s)	Penicillin G benzathine-procaine Penicillin G potassium, Penicillin G procaine, Penicillin G sodium, Penicillin V potassium, Penicillin G benzathine
Penicillinase-resistant penicillin(s)	Dicloxacillin, Nafcillin, Oxacillin
Quinolones	Ciprofloxacin, Gemifloxacin, Levofloxacin, Moxifloxacin, Ofloxacin
Rifamycin derivatives	Rifampin
Second generation cephalosporins	Cefaclor, Cefotetan, Cefoxitin, Cefprozil, Cefuroxime
Sulfonamides	Sulfadiazine, Sulfamethoxazole-trimethoprim
Tetracyclines	Doxycycline, Minocycline, Tetracycline
Third generation cephalosporins	Cefdinir, Cefixime, Cefotaxime, Cefpodoxime, Ceftriaxone, Ceftazidime
Urinary anti-infectives	Fosfomycin, Nitrofurantoin, Nitrofurantoin macrocrystals-monohydrate, Trimethoprim

Some conditions and/or diagnoses, if documented in the medical evaluation, will designate your patient as excluded from this HEDIS metric. For some measures, evidence of prior medical and prescription history can also exclude a patient from consideration.

Exclusions

- **Negative Medication History:** A period of 30 days prior to an episode whereby the patient has not had any antibiotic medications dispensed
- **Negative Condition History:** A period of 12 months prior to the episode whereby the patient has not been diagnosed with any of the following competing conditions: human immunodeficiency virus, malignant neoplasm, emphysema, chronic obstructive pulmonary disease, immune system disorders and other comorbid conditions (tuberculosis, sickle cell anemia, respiratory failure, and others)

Continued next page

HEDIS Measure: Appropriate Treatment for Upper Respiratory Treatment (URI) *(continued)*

Exclusions

- **Competing Diagnosis:** A period of three days following the episode date whereby the patient has had a competing diagnosis including cholera, typhoid, whooping cough, and others
- **Members in hospice or using hospice service anytime during the measurement year**
- **Members who died any time during the measurement year**

Content reproduced with permission from *HEDIS® MY 2023, Volume 2: Technical Specifications for Health Plans* by the National Committee for Quality Assurance (NCQA). HEDIS measures and specifications are not clinical guidelines and do not establish a standard of medical care. NCQA makes no representations, warranties, or endorsement about the quality of any organization or physician that uses or reports performance measures and NCQA has no liability to anyone who relies on such measures or specifications. Limited proprietary coding sets are contained in the specifications for convenience, and users should obtain all necessary licenses from the owners of the code sets. NCQA disclaims all liability for use or accuracy of any coding contained in the specifications. To purchase copies of the publication, including the full measures and specifications, visit [ncqa.org/publications](https://www.ncqa.org/publications).